Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

A Day Of Mergers: TIF, AMTD, MDCO & More

Published 11/24/2019, 10:32 PM
Updated 07/09/2023, 06:31 AM

Expect to hear a lot of talk about consumer spending this week — it’s the Monday before Black Friday, and we’ve got a three-day trading week, ending Wednesday afternoon. As such, we’ll see somewhat fewer economic data reports, and Q3 earnings season is starting to wrap up.

But first, speaking of “wrapping up”…

This morning is the biggest Merger Monday we’ve seen in quite some time. Beginning with the sale of Tiffany & Co. (NYSE:TIF) to French luxury conglomerate LVMH (Louis Vuitton Moët Hennessy) for $16.2 billion, or $135 per share. This is higher than the $14.5 billion offer from LVMH a month ago, at which time Tiffany’s share price shot up 32% on the news. In today’s pre-market, Tiffany shares are up an additional 5.7%, with LVMH up 1.2%.

Analyst look for this deal to boost Tiffany’s lagging international sales performance. The French luxury giant — which also owns Christian Dior, Bulgari and dozens of other brands — would likely consider this its wheelhouse; thus we like the synergies of this deal based on reports we’ve seen thus far.

Also, as initially reported last week, Charles Schwab (NYSE:SCHW) will indeed go ahead with its buyout of TD Ameritrade (NASDAQ:AMTD) for $26 billion, in an all-stock transaction. Combined, this company will control a whopping $5 trillion-plus in assets under management. This should also effectively bring an end to the trading services price war between the two companies. Ameritrade shares are up 3.5% on the news, while Schwab is down 0.43% at this hour.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Medicines Company (NASDAQ:MDCO) has agreed to terms with Swiss pharmaceutical giant Novartis (NYSE:NVS) , and will be purchased for $9.7 billion, or $85 per share, in all cash. This is a 45% premium from the trading close of Medicines Co. prior to this transaction first being announced. Chief among assets entering Novartis’ portfolio is inclisiran, a cardiovascular drug that may “revolutionize” treatment of the disease. Medicines Co. shares are up 22.7% in today’s pre-market, while Novartis stock is down only 0.04%. The expected close for this deal is early next year.

This morning, word is that eBay (NASDAQ:EBAY) will sell its StubHub business to another Swiss company, Viagogo, for $4.05 billion in all cash. The StubHub business had been dangled since last summer, and it looks as though it now has a taker. The sale is expected to complete in the first quarter of 2020.



eBay Inc. (EBAY): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

TD Ameritrade Holding Corporation (AMTD): Free Stock Analysis Report

The Charles Schwab Corporation (SCHW): Free Stock Analysis Report

The Medicines Company (MDCO): Free Stock Analysis Report

Tiffany & Co. (TIF): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.